JAMA sub-issue: More than 90% of cancer patients develop antibodies after COVID-19 vaccination!

Since the outbreak of the new crown epidemic, the cumulative number of confirmed cases worldwide has exceeded 460 million, and the cumulative number of deaths has exceeded 6.
072 million.
However, the recent global epidemic situation remains severe and complex
.

As the World Health Organization ( WHO ) warned, " As long as the new crown epidemic is still raging on the earth, as long as the vigilance is relaxed, the virus may mutate and spread at any time, triggering a new round of global epidemics

Since the outbreak of the new crown epidemic, the cumulative number of confirmed cases worldwide has exceeded 460 million, and the cumulative number of deaths has exceeded 6.

CCO

CCO

In the face of the fluctuating epidemic situation, receiving a total new crown vaccine has become the most effective and economical method at present
.

While multiple studies have shown that vaccination can prevent infection or reduce the risk of serious illness in healthy individuals, it is unclear whether those who are immunocompromised have a similar response, especially for cancer patients

In the face of the fluctuating epidemic situation, receiving a total new crown vaccine has become the most effective and economical method at present

In this cohort study, researchers followed 515 patients with solid tumors and hematological tumors, evaluating the patients' immune responses to themRNA-1273 vaccine

The results showed that the vast majority of cancer patients seroconverted, meaning they developed antibodies after being vaccinated

Antibody titers 28 days after 2 vaccinations

Antibody titers at 28 days after 2 vaccinations Antibody titers at 28 days after 2 vaccinations

Percent seropositivity before vaccination and after 1 and 2 doses of vaccine

Percent seropositivity before and after 1 and 2 doses of vaccine Percent seropositivity before and after 1 and 2 doses of vaccine

" Despite higher seroconversion rates in patients with solid tumors, antibody titers are still lower than in healthy individuals ," the researchers said.

"It is even more regrettable that we do not know how many antibodies the body needs to provide full protection against the virus .
In addition, Lymphatic diseases affect B cells, which the immune system needs to make antibodies .
If a patient's B cells are suppressed, they all have a low chance of making antibodies .
"

" Despite higher seroconversion rates in patients with solid tumors, antibody titers are still lower than in healthy individuals ," the researchers said.
"It is even more regrettable that we do not know how many antibodies the body needs to provide full protection against the virus .
In addition, Lymphatic diseases affect B cells, which the immune system needs to make antibodies .
If a patient's B cells are suppressed, they all have a low chance of making antibodies .
"

The Lancet previously reported that tumor patients treated with anti- CD20 antibodies had no immune response within six months of vaccination .

Patients receiving BTK inhibitors, Venetoclax , and CD19 - targeted CAR-T cells had the lowest seroconversion rates .

The Lancet previously reported that tumor patients treated with anti- CD20 antibodies had no immune response within six months of vaccination .
Patients receiving BTK inhibitors, Venetoclax , and CD19 - targeted CAR-T cells had the lowest seroconversion rates .

The researchers are continuing to follow study participants, taking blood samples at 6 , 12 and 24 months

In conclusion, the results of this cohort study suggest that patients with solid tumors or hematological tumors develop an immune response following vaccination with COVID-19 , albeit with lower antibody levels than those with a solid tumor or hematological tumor.
adults without cancer

original provenance

Anna R.

Giuliano et al, Evaluation of Antibody Response to SARS-CoV-2 mRNA-1273 Vaccination in Patients With Cancer in Florida , JAMA Oncology (2022).
  DOI: 10.

Anna R.
Giuliano et al, Evaluation of Antibody Response to SARS-CoV-2 mRNA-1273 Vaccination in Patients With Cancer in Florida , JAMA Oncology (2022).
  DOI: 10.
1001/jamaoncol.
2022.
0001 Evaluation of Antibody Response to SARS-CoV- 2 mRNA-1273 Vaccination in Patients With Cancer in Florida DOI: 10.
1001/jamaoncol.
2022.
0001 Leave a comment here